Business
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of Eos SENOLYTIX, Inc. ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common stock at a price per share of $2.20.
About this update from Pulmatrix, Inc.
[{"type":"text","content":"Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process ","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of Eos SENOLYTIX, Inc. ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common stock at a price per share of $2.20.","length":508,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Pulmatrix, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Pulmatrix, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":115,"url":"https://media.zenfs.com/en/prnewswire.com/abe963bfa73f037d806674de8b103712"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HeZ.jkp07nB471jIwKKL2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwMw--/https://media.zenfs.com/en/prnewswire.com/abe963bfa73f037d806674de8b103712","width":400,"height":115}},"href":"https://mma.prnewswire.com/media/1078018/Pulmatrix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The aggregate gross proceeds to the Company from the offering were approximately $1 million, before deducting offering expenses payable by the Company. The Company currently intends to use the permitted net proceeds from the offering for working capital and other general corporate purposes.","length":291,"tagName":"p"},{"type":"text","content":"Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, commented, "We have taken an important initial step forward as part of the planned merger and are pleased that investors supporting Eos chose to make this investment in Pulmatrix as part of the signing of the definitive merger agreement."","length":308,"tagName":"p"},{"type":"text","content":"The Series B Preferred Stock was issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the Se...